BRPI0519923A2 - polypeptide, dna sequence, dna vector, antibody, bacterium, method for producing partially 3-o-deacylated lps, composition, uses of the bacterium, and isolated bordetella lps comprising at least partially 3-o-deacylated lps, vaccine, and, in vitro method for deacylating gram-negative lps or compositions comprising gram-negative lps. - Google Patents
polypeptide, dna sequence, dna vector, antibody, bacterium, method for producing partially 3-o-deacylated lps, composition, uses of the bacterium, and isolated bordetella lps comprising at least partially 3-o-deacylated lps, vaccine, and, in vitro method for deacylating gram-negative lps or compositions comprising gram-negative lps.Info
- Publication number
- BRPI0519923A2 BRPI0519923A2 BRPI0519923-9A BRPI0519923A BRPI0519923A2 BR PI0519923 A2 BRPI0519923 A2 BR PI0519923A2 BR PI0519923 A BRPI0519923 A BR PI0519923A BR PI0519923 A2 BRPI0519923 A2 BR PI0519923A2
- Authority
- BR
- Brazil
- Prior art keywords
- lps
- gram
- negative
- bacterium
- deacylated
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000588807 Bordetella Species 0.000 title abstract 2
- 108020004414 DNA Proteins 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002158 endotoxin Substances 0.000 abstract 9
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 9
- 230000000694 effects Effects 0.000 abstract 2
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 244000000058 gram-negative pathogen Species 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
POLIPEPTìDEO, SEQüêNCIA DE DNA, VETOR DE DNA, ANTICORPO, BACTéRIA, MéTODO PARA PRODUZIR LPS PARCIALMENTE 3-O-DESACILADO, COMPOSIçãO, USOS DA BACTERIA, E DE LPS DE BORDETELLA ISOLADO COMPREENDENDO LPS PELO MENOS PARCIALMENTE 3-O-DESACILADO, VACINA, E, MéTODO IN VITRO PARA A DESACILAçãO DE LPS GRAM-NEGATIVO OU DE COMPOSIçõES COMPREENDENDO LPS GRAM-NEGATIVO. A presente invenção proporciona novos polipeptídeos Gram- negativos exibindo atividade de lipídeo A 3-O-desacilase e que são capazes de modificar e/ou desintoxicar LPS Gram-negativos. A presente invenção também proporciona bactérias Gram-negativas, lipopolissacarídeos (LPS) de bactérias Gram-negativas e composições compreendendo LPS, que são proporcionadas com ou tratadas com uma atividade de 3-O-desacilase de acordo com a invenção e que podem ser utilizadas para propósitos farmacêuticos e/ou veterinários, em particular para a preparação de vacinas acelulares ou de célula inteira contra patógenos Gram-negativos tais como Bordeteila pertuss is, Bordeteila parapertuss is, e Bordetelia bronchiseptica.Polypeptide, DNA Sequence, DNA VECTOR, ANTIBODY, BACTERIA, METHOD FOR PRODUCING PARTIALLY 3-O-DISABLED LPS, COMPOSITION, USES OF BACTERIA, AND LPS OF BORDETELLA ISOLATED COMPLETE LACIN-LPS PLATE AND, IN VITRO METHOD FOR DISABILING GRAM NEGATIVE LPS OR COMPOSITIONS UNDERSTANDING GRAM NEGATIVE LPS. The present invention provides novel Gram-negative polypeptides exhibiting 3-O-deacylase lipid A activity and which are capable of modifying and / or detoxifying Gram-negative LPS. The present invention also provides Gram-negative bacteria, Gram-negative lipopolysaccharide (LPS) bacteria, and compositions comprising LPS, which are provided with or treated with a 3-O-deacylase activity according to the invention and which may be used for pharmaceutical and / or veterinary purposes, in particular for the preparation of acellular or whole cell vaccines against Gram-negative pathogens such as Bordeteila pertussis, Bordeteila parapertussis, and Bordetelia bronchiseptica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04078445 | 2004-12-17 | ||
| PCT/NL2005/050081 WO2006065139A2 (en) | 2004-12-17 | 2005-12-16 | Deacylation of lps in gram negative bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0519923A2 true BRPI0519923A2 (en) | 2009-08-11 |
| BRPI0519923A8 BRPI0519923A8 (en) | 2018-01-23 |
Family
ID=34928754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519923A BRPI0519923A8 (en) | 2004-12-17 | 2005-12-16 | polypeptide, dna sequence, dna vector, antibody, bacterium, method for producing partially 3-0-deacylated lps, composition, uses of the bacterium, and isolated bordetella lps comprising at least partially 3-0-deacylated lps, vaccine, and, in vitro method for deacylating gram-negative lps or compositions comprising gram-negative lps, and for inducing an immune response against bordetella. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8048433B2 (en) |
| EP (1) | EP1828378B1 (en) |
| JP (1) | JP5378685B2 (en) |
| CN (1) | CN101203605B (en) |
| AU (1) | AU2005317304B2 (en) |
| BR (1) | BRPI0519923A8 (en) |
| CA (1) | CA2590906C (en) |
| DK (1) | DK1828378T3 (en) |
| ES (1) | ES2493440T3 (en) |
| MX (1) | MX2007007288A (en) |
| NO (1) | NO340331B1 (en) |
| NZ (1) | NZ555889A (en) |
| PL (1) | PL1828378T3 (en) |
| PT (1) | PT1828378E (en) |
| WO (1) | WO2006065139A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2393682T3 (en) * | 2007-03-26 | 2012-12-27 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Enhanced vaccines against Bordotella pertussis based on LPS glycosyltransferase mutants |
| WO2014024026A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| EP3006450B1 (en) | 2013-06-04 | 2020-07-29 | Aparin, Petr Gennadievich | Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants) |
| US11052142B2 (en) | 2013-06-04 | 2021-07-06 | Petr G. Aparin | Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants) |
| AU2014304545A1 (en) | 2013-08-05 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| WO2015179270A2 (en) | 2014-05-19 | 2015-11-26 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
| CN104388368B (en) * | 2014-10-30 | 2017-02-15 | 四川农业大学 | Low-endotoxin escherichia coli prokaryotic expression engineering bacterial mutant strain and construction method |
| CA3011282A1 (en) * | 2016-01-28 | 2017-08-03 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport | Modified tetra-acylated neisserial lps |
| CN105567620B (en) * | 2016-01-29 | 2019-03-19 | 江南大学 | A Cronobacter sakazakii mutant strain producing attenuated lipid A and its application |
| CN105695540A (en) * | 2016-03-18 | 2016-06-22 | 辽宁成大生物股份有限公司 | Preparing method of gram-negative bacterium cell wall antigen |
| BR112019018905A2 (en) | 2017-03-13 | 2020-05-19 | De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport | vaccines against bordetella comprising lps with reduced reactogenicity |
| WO2018213242A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Maryland, Baltimore | Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof |
| BR112020011019A2 (en) * | 2017-12-04 | 2020-11-17 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport | improved process to produce outer membrane vesicles |
| CN115552020B (en) * | 2020-05-14 | 2026-01-09 | 默克专利股份公司 | Methods and compositions for purifying adeno-associated virus particles or adenovirus |
| US20250263447A1 (en) | 2020-09-04 | 2025-08-21 | Intravacc B.V. | Ompa mutations enhance omv production in bordetella pertussis |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH650681A5 (en) * | 1981-08-14 | 1985-08-15 | Dso Pharmachim | Whooping cough vaccine |
| KR0168039B1 (en) * | 1987-09-04 | 1999-01-15 | 로버트 디. 웨스트 | Recombinant dna derived bordetella toxin subunit analogs |
| EP0484621A3 (en) * | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
| CZ285307B6 (en) * | 1992-08-18 | 1999-07-14 | Dimminaco Ag/Sa/Ltd. | Polypeptide exhibiting immunogenic properties of bordetella brochiseptica fimbria protein, recombinant polynucleotide capable of inducing expression of such polypeptide and vaccine against infections caused by bordetella brochiseptica bacteria |
| ATE221081T1 (en) * | 1995-05-04 | 2002-08-15 | Aventis Pasteur | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR THE PRODUCTION THEREOF |
| US6887483B2 (en) | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| NZ338101A (en) * | 1997-04-01 | 2002-03-28 | Corixa Corp | Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration |
| CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| AU762369B2 (en) * | 1998-11-03 | 2003-06-26 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | LPS with reduced toxicity from genetically modified gram negative bacteria |
| US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
| AU2002307448A1 (en) * | 2001-04-20 | 2002-11-05 | President And Fellows Of Harvard College | Methods and compositions for the modulation of biofilm formation |
-
2005
- 2005-12-16 CN CN200580048420.6A patent/CN101203605B/en not_active Expired - Fee Related
- 2005-12-16 BR BRPI0519923A patent/BRPI0519923A8/en not_active Application Discontinuation
- 2005-12-16 ES ES05815467.5T patent/ES2493440T3/en not_active Expired - Lifetime
- 2005-12-16 JP JP2007546589A patent/JP5378685B2/en not_active Expired - Fee Related
- 2005-12-16 CA CA2590906A patent/CA2590906C/en not_active Expired - Fee Related
- 2005-12-16 NZ NZ555889A patent/NZ555889A/en not_active IP Right Cessation
- 2005-12-16 US US11/722,034 patent/US8048433B2/en not_active Expired - Fee Related
- 2005-12-16 MX MX2007007288A patent/MX2007007288A/en active IP Right Grant
- 2005-12-16 PL PL05815467T patent/PL1828378T3/en unknown
- 2005-12-16 WO PCT/NL2005/050081 patent/WO2006065139A2/en not_active Ceased
- 2005-12-16 EP EP05815467.5A patent/EP1828378B1/en not_active Expired - Lifetime
- 2005-12-16 DK DK05815467.5T patent/DK1828378T3/en active
- 2005-12-16 AU AU2005317304A patent/AU2005317304B2/en not_active Ceased
- 2005-12-16 PT PT58154675T patent/PT1828378E/en unknown
-
2007
- 2007-06-18 NO NO20073088A patent/NO340331B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005317304B2 (en) | 2011-06-23 |
| BRPI0519923A8 (en) | 2018-01-23 |
| US8048433B2 (en) | 2011-11-01 |
| ES2493440T3 (en) | 2014-09-11 |
| NO20073088L (en) | 2007-09-17 |
| NO340331B1 (en) | 2017-04-03 |
| PT1828378E (en) | 2014-10-10 |
| EP1828378B1 (en) | 2014-06-11 |
| WO2006065139A3 (en) | 2006-10-19 |
| CN101203605A (en) | 2008-06-18 |
| MX2007007288A (en) | 2008-02-25 |
| DK1828378T3 (en) | 2014-09-01 |
| JP2008523805A (en) | 2008-07-10 |
| JP5378685B2 (en) | 2013-12-25 |
| WO2006065139A2 (en) | 2006-06-22 |
| CA2590906A1 (en) | 2006-06-22 |
| NZ555889A (en) | 2009-07-31 |
| CA2590906C (en) | 2017-01-03 |
| US20080274145A1 (en) | 2008-11-06 |
| PL1828378T3 (en) | 2014-10-31 |
| CN101203605B (en) | 2016-01-27 |
| EP1828378A2 (en) | 2007-09-05 |
| AU2005317304A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0519923A2 (en) | polypeptide, dna sequence, dna vector, antibody, bacterium, method for producing partially 3-o-deacylated lps, composition, uses of the bacterium, and isolated bordetella lps comprising at least partially 3-o-deacylated lps, vaccine, and, in vitro method for deacylating gram-negative lps or compositions comprising gram-negative lps. | |
| BRPI0411505A (en) | use of a compound, method for modulating an individual's immune response, pharmaceutical composition, vaccine, complex, and kit for capturing a biologically active molecule | |
| BR0210225A (en) | Mutant immunogenic cholera holotoxin, immunogenic composition, method for enhancing a vertebrate host's immune response to an antigen, isolated and purified DNA sequence, nucleic acid molecule, host cell, method for producing a mutant immunogenic cholera holotoxin, and, use of a mutant cholera holotoxin | |
| BR112022013753A2 (en) | SYNTHETIC COMPOSITION OF FUNCTIONALLY OPTIMIZED MICROBES AND METHOD | |
| Williams et al. | Catecholate receptor proteins in Salmonella enterica: role in virulence and implications for vaccine development | |
| WO2009104074A3 (en) | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells | |
| BRPI0517514A (en) | immunogenic bacterial vesicles with outer membrane proteins | |
| BRPI0620946A8 (en) | il-23p19 antibody isolated, composition, in vitro method, article of manufacture, nucleic acid vector and molecule, prokaryotic host cell | |
| ATE522541T1 (en) | BACTERIAL ADHESIN CONFORMERS | |
| BRPI0802049A2 (en) | cosmetic or dermatological composition, uses of at least one cell culture medium, cosmetic process for improving skin homeostasis and process for preparing a cosmetic or dermatological composition | |
| BRPI0409789B8 (en) | bacterial cell, its preparation processes and its use, composition, and process for the preparation of a live vaccine | |
| CO5680455A2 (en) | NEISSERIAL VACCINE COMPOSITIONS THAT INCLUDE AN ANTIGEN BINATION | |
| BRPI0801858A2 (en) | use of at least one conditioned cell culture medium or its cosmetic or dermatological extract and composition | |
| BRPI0515520A (en) | immunogenic composition, vaccine, methods of preparing a vaccine and preventing or treating staph infection, and use of immunogenic composition | |
| ES2096262T3 (en) | NEW MODIFIED CYCLOSPORINS IN POSITION 1. | |
| PE20061107A1 (en) | TIGECYCLINE COMPOSITIONS AND METHODS FOR ITS PREPARATION | |
| Gibbons et al. | Vitamin K compounds in bacteria that are obligate anaerobes | |
| AR033574A1 (en) | A BACTERIAL CEPA OF THE LACTIC BACTERIA GROUP CAPABLE OF REDUCING THE TREND OF AN INDIVIDUAL TO DEVELOP ALLERGIC REACTIONS, FOOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THE VACCINES CONTAINING IT | |
| Walter et al. | Moderate effect of enamel matrix derivative (Emdogain® Gel) on Porphyromonas gingivalis growth in vitro | |
| BRPI0410562A (en) | recombinant molecule and vehicle for expression, release and purification of target polypeptides | |
| BRPI0609692C1 (en) | fermentation and manufacturing processes of a preparation of an antigen from c. diphtheriae | |
| ATE544471T1 (en) | COMPOSITION WITH ISCOM PARTICLES AND LIVING MICROORGANISMS | |
| Yoshimura et al. | Proteome analysis of Porphyromonas gingivalis cells placed in a subcutaneous chamber of mice | |
| AU2017203173B2 (en) | Method For The Production Of Protein Complexes And Vaccine Compositions Comprising The Same | |
| BR0215124A (en) | Compounds and their uses, pharmaceutical and cosmetic compositions and cosmetic use of a cosmetic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
| B25A | Requested transfer of rights approved |
Owner name: DE STAAT DER NEDERLANDEN, VERTEGENWOORDIGD DOOR DE Free format text: TRANSFERIDO DE: NVI NEDERLANDS VACCININSTITUUT |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09R | Decision of refusal: republication [chapter 9.2.3 patent gazette] |
Free format text: REPUBLICACAO POR TER SIDO CONSTATADO ERRO MATERIAL. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |